<html xmlns="http://www.w3.org/1999/xhtml"><body><table style="border: 1px solid black;"><caption /><tr><th style="border: 1px solid black;">Study </th><th style="border: 1px solid black;">Category of risk factor reported </th><th style="border: 1px solid black;">Data source of study </th><th style="border: 1px solid black;">Sample size of study (N) </th><th style="border: 1px solid black;">Risk factor details </th></tr><tr><td style="border: 1px solid black;">Argyriou (2013)</td><td style="border: 1px solid black;">Genetic</td><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">200</td><td style="border: 1px solid black;">SNC4A-rs2302237 OR = 2.65 (1.15–6)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">SCN10A-rs1263292 OR = 0.39 (0.17–0.88)</td></tr><tr><td style="border: 1px solid black;">Attal (2009)</td><td style="border: 1px solid black;">Clinical</td><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">18</td><td style="border: 1px solid black;">Cold allodynia OR = 39 (1.8–817)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">Cold hyperalgesia OR = 3.9 (1.0–1.20)</td></tr><tr><td style="border: 1px solid black;">Baldwin (2012)</td><td style="border: 1px solid black;">Genetic</td><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">855</td><td style="border: 1px solid black;">FGD4-rs10771973 HR = 1.57 (1.30–1.91)</td></tr><tr><td style="border: 1px solid black;">Dimopoulos (2011)</td><td style="border: 1px solid black;">Clinical</td><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">340</td><td style="border: 1px solid black;">Baseline neuropathy HR = 1.79 (p &lt; 0.01)</td></tr><tr><td style="border: 1px solid black;">Glendenning (2010)</td><td style="border: 1px solid black;">Clinical and treatment-related</td><td style="border: 1px solid black;">Cross-sectional cohort</td><td style="border: 1px solid black;">293</td><td style="border: 1px solid black;">Cisplatin dose increase OR = 1.91 (1.61–2.26)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">Carboplatin dose increase OR = 1.26 (1.04–1.52)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">Age at follow-up OR = 1.06 (1.04–1.08)</td></tr><tr><td style="border: 1px solid black;">Johnson (2011) ^{⁄}</td><td style="border: 1px solid black;">Genetic</td><td style="border: 1px solid black;">RCT</td><td style="border: 1px solid black;">970 + 550</td><td style="border: 1px solid black;">ABCA1-rs363717 OR = 0.71 (0.52–0.98)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">ICAM1-rs1799969 OR = 0.67 (0.44–1.03)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">PPARD-rs2076169 OR = 0.60 (0.38–095)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">SERPINB2-rs6103 OR = 0.70 (0.52–0.95)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">SLC12A6-rs7164902 OR = 0.60 (0.44–0.80)</td></tr><tr><td style="border: 1px solid black;">Kawakami (2012)</td><td style="border: 1px solid black;">Clinical</td><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">50</td><td style="border: 1px solid black;">Smoking history pack-years HR = 1.03 (1.0–1.05)</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">Decreased creatinine clearance HR = 0.96 (0.92–0.99)</td></tr><tr><td style="border: 1px solid black;">Won (2012) ^{†}</td><td style="border: 1px solid black;">Genetic</td><td style="border: 1px solid black;">Prospective cohort</td><td style="border: 1px solid black;">96</td><td style="border: 1px solid black;">TAC1-rs10486003</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">FOXC1-rs2338</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">ITGA1-rs830884</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">ACYP2-rs843748</td></tr><tr><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;"></td><td style="border: 1px solid black;">DLEU7-rs797519</td></tr></table></body></html>